The Filing Desk

Surgery Partners

SGRY · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

SGRY · Last close · November 13, 2026
$26.95
Value Surgery Partners yourself

Surgery Partners' revenue rose 6.2% to $3.3 billion in fiscal 2025. Its operating margin was 11.8%, up from 11.2% a year earlier. Free cash flow was $196 million, down 6.7%. The diluted share count rose 0.9%.

Surgery Partners, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 2, 2026 · 0001638833-26-000008 Updated
Revenue
$3.3B
6.2%
Operating margin
11.8%
0.6 pts
Net income
−$78M
 
Free cash flow
$196M
6.7%
Return on capital
4.2%
0.1 pts
Market cap
$3.5B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Surgery Partners does

Surgery Partners owns and runs surgical centers across the United States. Its sites include ambulatory surgery centers (outpatient facilities where patients have an operation and go home the same day), short-stay surgical hospitals and physician practices. Most of its work is planned, non-emergency surgery in fields such as orthopedics and pain management, eye care, and stomach and bowel procedures.

It makes money from fees for the care given at its facilities, paid by insurers, government programs such as Medicare, and patients. It reports one segment, Surgical Facilities, which supplies nearly all of its revenue. The surgery centers and hospitals alone brought in approximately $3.2 billion in 2025. Doctors are often partial owners of its facilities, and the company seeks to be the partner for physicians who want to stay independent.

It operates more than 200 locations in 30 states. At the end of 2025 it owned or operated 157 ambulatory surgery centers and 19 surgical hospitals. It grows by recruiting physicians, adding services and buying more facilities.

Its biggest risks, as it describes them

  • Its facilities do not meet the safe harbors of the federal Anti-Kickback Statute, so a change in how regulators read it could bring penalties.
  • Cuts or changes in what Medicare, other government programs and insurers pay could reduce its revenue.
  • Changes in health care rules may force it to buy out physician partners or renegotiate its agreements with them.
  • Malpractice claims, audits and investigations could lead to large payments or lost revenue.
  • Federal law limits how much its surgical hospitals can expand.
From Surgery Partners's annual report on Form 10-K, filed March 2, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both. Where the filings' structured data doesn't give a year's net income, the column is blank.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Surgery Partners lost money in fiscal 2025: a net loss of $78 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments390283196270240
Debt incl. finance leases3,3233,2203,4974,2034,671
Net debt (negative means net cash)2,9332,9373,3023,9344,431
Net debt to EBITDA7.3x6.4x7.4x7.8x7.8x
Debt to equity3.0x1.6x1.8x2.4x2.7x
Interest coverage1.6x1.6x1.9x1.8x1.5x
Current ratio1.8x1.9x1.7x1.8x1.9x
Quick ratio1.6x1.7x1.6x1.6x1.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Surgery Partners' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $143,500 of Surgery Partners shares on the open market, and 6 insiders sold $1.3 million.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 18, 2026Teresa DeLucaDirectorBought10,000$14.35$143,500Form 4
Mar 16, 2026Jason Eric EvansChief Executive OfficerSold20,400$12.47$254,388Form 4
Mar 16, 2026David T DohertyChief Financial OfficerSold8,867$12.50$110,838Form 4
Mar 13, 2026Marissa BrittenhamChief Strategy OfficerSold3,657$12.54$45,859Form 4
Mar 13, 2026Danielle BurkhalterChief Human Resources OfficerSold3,469$12.83$44,507Form 4
Mar 12, 2026Jennifer BaldockChief Admin & Dev OfficerSold5,798$13.17$76,360Form 4
Mar 6, 2026David T DohertyChief Financial OfficerSold14,574$13.84$201,704Form 4
Mar 6, 2026Jason Eric EvansChief Executive OfficerSold11,462$13.79$158,061Form 4
Mar 6, 2026Jennifer BaldockChief Admin & Dev OfficerSold10,082$13.70$138,123Form 4
Mar 6, 2026Marissa BrittenhamChief Strategy OfficerSold8,785$13.70$120,354Form 4
Mar 6, 2026Danielle BurkhalterChief Human Resources OfficerSold7,736$13.60$105,210Form 4
Mar 6, 2026William Trenton WebbAmerican Group PresidentSold272$13.93$3,789Form 4
The latest 12 of 13 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 84 of 84 of 8
Rule of 4015.5%20.3%12.2%
Altman Z''1.231.121.09
Accruals ratio−4.5%−6.3%−4.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positivePassPassPass
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailFail
Current ratio roseFailPassPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailPassFail
F-score3 of 84 of 84 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Surgery Partners side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Surgery PartnersFY256.2%11.8%5.9%4.2%7.8x4
Acadia HealthcareFY255.0%—−13.3%−16.0%—4Compare
Brookdale Senior LivingFY252.2%0.4%0.5%0.3%10.5x4Compare
Astrana HealthFY2556.4%2.5%3.3%4.2%4.9x4Compare
Ensign GroupFY2518.7%8.4%—19.7%−0.8x6Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue1,145—1,7721,8311,8602,2252,5392,7433,1143,309
Revenue growth19.3%——3.4%1.6%19.6%14.1%8.0%13.5%6.2%
Gross profit324—410424——————
Research and development——————————
Operating income196—78236183302345328349390
Net income10—−206−75−116−71−55−12−168−78
Diluted EPS (US$)0.20—−4.96−2.29−3.19−1.12−0.59−0.09−1.33−0.61
Diluted shares (millions)48—4848497292126126127
Cash flow
Cash from operations125—14513024787159294300274
Capital expenditure39—4074435881899079
Free cash flow86—105562043078205210196
Dividends paid0000000000
Share buybacks0020000000
Acquisitions14601071410528614680379162
Stock-based compensation2—910131718183315
Balance sheet at fiscal year end
Cash and short-term investments7017518493318390283196270240
Debt incl. finance leases1,4742,1862,3542,8503,1583,3233,2203,4974,2034,671
Total assets2,3054,6234,6765,0195,4136,1186,6826,8777,8908,120
Total liabilities1,9803,2863,5774,0364,5314,1483,7413,8424,6944,988
Shareholders' equity106554052971161,0891,9981,9871,7901,713
Margins and ratios
Gross margin28.3%—23.1%23.1%——————
Operating margin17.1%—4.4%12.9%9.8%13.6%13.6%12.0%11.2%11.8%
Net margin0.8%—−11.6%−4.1%−6.2%−3.2%−2.1%−0.4%−5.4%−2.4%
Free cash flow margin7.5%—5.9%3.0%11.0%1.3%3.1%7.5%6.7%5.9%
Rule of 40 (growth + FCF margin)26.9%——6.4%12.5%20.9%17.2%15.5%20.3%12.2%
Return on capital6.9%—1.9%5.3%3.9%5.5%5.1%4.2%4.1%4.2%
Return on equity——−38.8%−21.3%—−11.8%−3.5%−0.6%−8.9%−4.5%
Return on assets0.4%—−4.4%−1.5%−2.2%−1.2%−0.8%−0.2%−2.3%−1.0%
Net debt to EBITDA6.0x—14.9x8.8x10.2x7.3x6.4x7.4x7.8x7.8x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Surgery Partners' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Surgery Partners.